NCT04232878View on ClinicalTrials.gov

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

March 6, 2020

Study Completion Date

May 21, 2020

Conditions
Substance Use Disorders (SUD)
Interventions
DRUG

CVL-936

CVL-936

DRUG

Matching Placebo

Placebo matching CVL-936

Trial Locations (1)

08053

Hassman Research Institute, Marlton

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT04232878 - A Single Ascending Dose Trial of CVL-936 in Healthy Subjects | Biotech Hunter | Biotech Hunter